Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem
12 nov. 2024 08h00 HE
|
Araris Biotech
First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
07 nov. 2024 08h30 HE
|
Vaccinex, Inc.
Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
MacroGenics to Participate in Upcoming Investor Conferences
06 nov. 2024 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
05 nov. 2024 16h01 HE
|
MacroGenics, Inc.
Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed...
MacroGenics Announces Leadership Transition
30 oct. 2024 07h30 HE
|
MacroGenics, Inc.
Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:...
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
29 oct. 2024 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10 oct. 2024 21h00 HE
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
01 oct. 2024 08h00 HE
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs)
24 sept. 2024 08h00 HE
|
Araris Biotech
Araris Biotech AG Expands its IP Portfolio with the Acquisition of Innate Pharma’s Portfolio of Transglutaminase Patents for the Generation of Antibody-Drug Conjugates (ADCs) AU ZH, SWITZERLAND,...
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
15 sept. 2024 03h00 HE
|
MacroGenics, Inc.
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORRPatients remained on vobra duo through a median of 6 doses (ranging up to 12), representing...